论文部分内容阅读
目的探讨拉米夫定联合阿德福韦酯治疗乙型肝炎抗病毒初治症的临床疗效。方法选取120例乙型肝炎抗病毒初治症患者,将其随机分为3组,A组患者给予拉米夫定治疗,B组患者给予阿德福韦酯治疗,C组患者给予拉米夫定联合阿德福韦酯治疗,治疗48周。治疗后分别于第12、24、48周观察各组患者乙型肝炎病毒脱氧核糖核酸(HBV-DNA)转阴率、乙型肝炎e抗原(HBe Ag)转阴率、血清丙氨酸转氨酶(ALT)复常率、HBe Ag/抗-HBe血清转换率及不良反应发生情况。结果治疗12、24、48周后,C组患者的HBV-DNA转阴率、HBe Ag转阴率、血清ALT复常率、HBe Ag/抗-HBe血清转换率均明显高于A组和B组,差异有统计学意义(P<0.05),3组均未出现不良反应,无1例停药,患者耐受性均良好。结论拉米夫定联合阿德福韦酯治疗乙型肝炎抗病毒初治症临床疗效优于单独使用拉米夫定或阿德福韦酯治疗,安全性好。
Objective To investigate the clinical efficacy of lamivudine combined with adefovir dipivoxil in the treatment of hepatitis B virus (HBV) naive disease. Methods 120 cases of hepatitis B virus-naive patients were randomly divided into three groups, patients in group A received lamivudine, patients in group B received adefovir dipivoxil, and patients in group C received lamivudine Adefovir dipivoxil treatment, for 48 weeks. After treatment, the negative rate of hepatitis B virus DNA (HBV-DNA), negative rate of hepatitis B e antigen (HBeAg), serum alanine aminotransferase ALT) normalization rate, HBe Ag / anti-HBe seroconversion rate and adverse reactions. Results After 12, 24 and 48 weeks of treatment, the rates of HBV DNA negative conversion, HBe Ag negative conversion, serum ALT normalization and HBe Ag / anti-HBe conversion were significantly higher in group C than those in group A and B Group, the difference was statistically significant (P <0.05), 3 groups were no adverse reactions, no one withdrawal, the patient was well tolerated. Conclusion lamivudine combined with adefovir dipivoxil treatment of hepatitis B anti-virus naive disease clinical efficacy than lamivudine alone or adefovir dipivoxil treatment, good safety.